The journal said that the domestically developed vaccine is “safe, well-tolerated and immunogenic in pediatric subjects.” Bharat Biotech confirmed the development in a tweet.
The company has been asked to submit safety data including data on adverse events with due analysis every 15 days for the first two months and monthly after upto 5 months.
Indian govt had recently said that the supply of COVAXIN through UN procurement agencies will not impact travel by people who have taken the vaccine after WHO's suspension.
WHO Director General Tedros Adhanom Ghebreyesus made the remarks a day after the WHO granted emergency use approval for Bharat Biotech’s COVID-19 vaccine Covaxin.
Bharat Biotech recently said it submitted all data pertaining to Covaxin to the WHO for emergency use and is awaiting feedback from the global health watchdog.